Ocugen, Inc. Profile Avatar - Palmy Investing

Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function…

Biotechnology
US, Malvern [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Ocugen, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Ocugen, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Ocugen, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of OCGN's Analysis
CIK: 1372299 CUSIP: 67577C105 ISIN: US67577C1053 LEI: - UEI: -
Secondary Listings
OCGN has no secondary listings inside our databases.